178311-50-7

Basic information

• Product Name: 1-BOC-3-[(2-HYDROXYETHYL)AMINO]-AZETIDINE
• Synonyms: 1-BOC-3-[(2-HYDROXYETHYL)AMINO]-AZETIDINE;tert-butyl 3-(2-hydroxyethylamino)azetidine-1-carboxylate
• CAS NO: 178311-50-7
• Molecular Formula: C10H20N2O3
• Molecular Weight: 216.28
• Mol File: 178311-50-7.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1-BOC-3-[(2-HYDROXYETHYL)AMINO]-AZETIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-BOC-3-[(2-HYDROXYETHYL)AMINO]-AZETIDINE(178311-50-7)
• EPA Substance Registry System: 1-BOC-3-[(2-HYDROXYETHYL)AMINO]-AZETIDINE(178311-50-7)

Safety Data

• Hazardous Substances Data: 178311-50-7(Hazardous Substances Data)

Usage

Chemical Class

Azetidine

Functional Groups

BOC (tert-butoxycarbonyl) protecting group
Hydroxyethylamine group

Structure

A four-membered nitrogen-containing ring (azetidine)
A methyl group attached to the 3-position of the azetidine ring
A hydroxyethylamine group attached to the 2-position of the azetidine ring
A BOC protecting group attached to the nitrogen atom of the hydroxyethylamine group

Applications

Medicinal chemistry
Synthesis of other bioactive molecules

Industry Applications

Chemical industry
Pharmaceutical industry

Protecting Group

BOC group is used to protect amines during organic synthesis

Potential Uses

As an intermediate for the synthesis of various bioactive molecules
In the development of new drugs and pharmaceuticals

Upstream product

• 398489-26-4 tert-butyl 3-oxoazetidine-1-carboxylate 
• 141-43-5 ethanolamine 

Relevant articles and documents

NITROGEN OXIDE-DONATING PDE-5 AND/OR PDE-6 INHIBITOR COMPOUNDS

The present disclosure provides phosphodiesterase 5 (PDE-5) and/or phosphodiesterase 6 (PDE-6) inhibitor compounds and compositions including said compounds. In some embodiments, said compounds are nitrogen oxide (NO) donating PDE-5 and/or -6 inhibitor compounds that include a nitrogen oxide-containing donor substituent attached to a benzenesulfonamide group. The compounds can provide dual functionality for increasing protein kinase G (PKG) activity by inhibiting PDE-5 and PDE-6, and/or stimulating guanylate cyclase (sGC) via donation of nitrogen oxide (NO) from the donor substituent of the compound. The present disclosure also provides methods of using said compounds and compositions for inhibiting PDE-5 and/or -6 and increasing activity of protein kinase G (PKG). The compounds and compositions find use in therapeutic applications including in the treatment of a variety of eye diseases. For example, the subject compounds may be used as a therapeutic agent for glaucoma, age-related macular degeneration (AMD), diabetic retinopathy (DR), xerophthalmia, cataracts or uveitis.

QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS

Compounds that are Fibroblast Growth Factor Inhibitors (FGFR) and are therefore useful for the treatment of diseases treatable by inhibition of FGFR are disclosed. Also disclosed are pharmaceutical compositions containing such compounds and processes for

TREATMENT OF URINARY TRACT INFECTIONS WITH ANTIBACTERIAL AMINOGLYCOSIDE COMPOUNDS

A method for treating a urinary tract infection in a mammal in need thereof is disclosed, the method comprising administering to the mammal an effective amount of an antibacterial aminoglycoside compound.

ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS

Compounds of structure (I): having antibacterial activity are disclosed, including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein Q1, Q2, Q3, R8 and R9 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.